

1. General Information

Cohort ID	5005_13
Title (Study Name)	Neurology Collection
Principal investigator	Assoz.Prof. Michael Khali, Prof. Juan-Jose Archelos-Garcia
Contact information	pm-biobank@medunigraz.at
Funding agency	-----

2. Description

Focus on neuroimmunological and neurodegenerative disorders.

Large control sample collection, including:

- Inflammatory neurological disease controls (INDCs)
- Peripheral inflammatory neurological disease controls - (PINDCs)
- Non-inflammatory neurological disease controls (NINDCs)
- Symptomatic controls (SCs)

3. Details

ICD 10/O codes / Healthy	Main ICD 10 codes include: G35-G37, G20-G26, F03, G60-G64, G44, R20.	
Key words	neurodegeneration, neuroinflammation, controls, lumbar puncture, cerebrospinal fluid, serum, biomarkers	
Collection / Cohort size 11/2021	16.573 aliquots from 1.513 patients	
Informed Consent (IC)	<input checked="" type="checkbox"/> Broad Biobank IC	
	<input type="checkbox"/> Specific Study IC	
Status	<input checked="" type="checkbox"/> In progress / compl. date: open	
	<input type="checkbox"/> Completed	
Inclusion criteria	Age distribution	18+
	Sex distribution (f:m)	~ 50:50
	Others	-----
Earliest access	As of now	
Quality-standards	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
Associated publications / references	Selected publications: <u>CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS</u> Fissolo, N; Matute-Blanch, C; Osman, M; Costa, C; Pinteac, R; Miró, B; Sanchez, A; Brito, V; Dujmovic, I; Voortman, M; Khalil, M; Borràs, E; Sabidó, E; Issazadeh-Navikas, S; Montalban, X; Comabella Lopez, M.	
	<u>Decreased Cerebrospinal Fluid Antioxidative Capacity Is Related to Disease Severity and Progression in Early Multiple Sclerosis.</u> Voortman, MM; Damulina, A; Pirpamer, L; Pinter, D; Pichler, A; Enzinger, C; Ropele, S; Bachmaier, G; Archelos, JJ; Marsche, G; Khalil, M.	

	<p><u>Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.</u> Leurs, CE; Twaalfhoven, H; Lissenberg-Witte, BI; van Pesch, V; Dujmovic, I; Drulovic, J; Castellazzi, M; Bellini, T; Pugliatti, M; Kuhle, J; Villar, LM; Alvarez-Cermeño, JC; Alvarez-Lafuente, R; Hegen, H; Deisenhammer, F; Walchhofer, LM; Thouvenot, E; Comabella, M; Montalban, X; Vécsei, L; Rajda, C; Galimberti, D; Scarpini, E; Altintas, A; Rejdak, K; Frederiksen, JL; Pihl-Jensen, G; Jensen, P; Khalil, M; Voortman, MM; Fazekas, F; Saiz, A; La Puma, D; Vercammen, M; Vanopdenbosch, L; Uitdehaag, B; Killestein, J; Bridel, C; Teunissen, C. https://pubmed.ncbi.nlm.nih.gov/31066634/</p> <p><u>Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis.</u> Chatterjee, M; Koel-Simmelink, MJ; Verberk, IM; Killestein, J; Vrenken, H; Enzinger, C; Ropele, S; Fazekas, F; Khalil, M; Teunissen, CE. https://pubmed.ncbi.nlm.nih.gov/30627437/</p> <p><u>Mucosal biopsy shows immunologic changes of the colon in patients with early MS.</u> Moser, AM; Spindelboeck, W; Strohmaier, H; Enzinger, C; Gattringer, T; Fuchs, S; Fazekas, F; Gorkiewicz, G; Wurm, P; Högenauer, C; Khalil, M. https://pubmed.ncbi.nlm.nih.gov/28638851/</p>
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

4. Material available (aliquot size) and storage conditions

Material	<input checked="" type="checkbox"/> Serum (400 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> Cerebrospinal fluid - CSF (580 µl)	<input checked="" type="checkbox"/> -80°C
	<input checked="" type="checkbox"/> CSF cells (400 µl)	<input checked="" type="checkbox"/> -80°C

Dokument erstellt (tt/mm/yyyy): 16/09/2021	Letzte inhaltliche Aktualisierung (tt/mm/yyyy): 18/02/2022
------------------------------------------------------	----------------------------------------------------------------------